Melanotan-2
MT-II, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
Synthetic analogue of α-MSH that stimulates melanogenesis for skin tanning and may increase sexual arousal.
Completed
PHASE2
NCT02315430
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT00023751
Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer
Alliance for Clinical Trials in Oncology
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT00000820
A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy
National Institute of Allergy and Infectious Diseases (NIAID)
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT00217620
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT05519475
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Regeneron Pharmaceuticals
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE3
NCT00005834
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
SWOG Cancer Research Network
INTERVENTIONAL
Updated Dec 15, 2025
Withdrawn
NA
NCT03978182
Accelerated Deep TMS in the Elderly Depressed: A Brain Imaging Approach
Universitair Ziekenhuis Brussel
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT00047840
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
Genzyme, a Sanofi Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2, PHASE3
NCT02152982
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT00005832
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
SWOG Cancer Research Network
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT05904080
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT02834013
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT03976323
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT00066846
Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
National Cancer Institute (NCI)
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE2, PHASE3
NCT05011513
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
Pfizer
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT04822181
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NA
NCT06887647
PT for Montana Children With NMD Using Hippotherapy and the Equine Environment
University of Montana
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT03056755
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
Novartis Pharmaceuticals
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT01809691
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
SWOG Cancer Research Network
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT06992427
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Alliance for Clinical Trials in Oncology
INTERVENTIONAL
Updated Dec 15, 2025